Equities analysts expect Ovid Therapeutics Inc (NASDAQ:OVID) to announce ($0.49) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Ovid Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.51) and the highest estimate coming in at ($0.46). Ovid Therapeutics posted earnings per share of ($0.53) in the same quarter last year, which would suggest a positive year over year growth rate of 7.5%. The business is scheduled to announce its next earnings results on Thursday, August 8th.
On average, analysts expect that Ovid Therapeutics will report full-year earnings of ($1.84) per share for the current financial year, with EPS estimates ranging from ($2.15) to ($1.52). For the next year, analysts anticipate that the company will report earnings of ($2.41) per share, with EPS estimates ranging from ($4.55) to ($0.53). Zacks’ EPS calculations are a mean average based on a survey of research analysts that that provide coverage for Ovid Therapeutics.
Ovid Therapeutics (NASDAQ:OVID) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.04).
Several hedge funds and other institutional investors have recently modified their holdings of OVID. Acadian Asset Management LLC raised its stake in Ovid Therapeutics by 445.6% during the first quarter. Acadian Asset Management LLC now owns 153,898 shares of the company’s stock worth $272,000 after acquiring an additional 125,690 shares in the last quarter. Two Sigma Investments LP acquired a new position in Ovid Therapeutics during the fourth quarter worth $114,000. SG Americas Securities LLC acquired a new position in Ovid Therapeutics during the fourth quarter worth $46,000. Dimensional Fund Advisors LP raised its stake in Ovid Therapeutics by 11.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 87,257 shares of the company’s stock worth $211,000 after acquiring an additional 8,995 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in Ovid Therapeutics by 7.1% during the fourth quarter. Geode Capital Management LLC now owns 95,865 shares of the company’s stock worth $231,000 after acquiring an additional 6,391 shares in the last quarter. Institutional investors and hedge funds own 31.73% of the company’s stock.
Shares of OVID traded down $0.01 during mid-day trading on Monday, hitting $1.77. The company’s stock had a trading volume of 1,719 shares, compared to its average volume of 151,817. Ovid Therapeutics has a one year low of $1.53 and a one year high of $11.45. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.78 and a quick ratio of 7.78. The firm has a market capitalization of $68.49 million, a price-to-earnings ratio of -0.84 and a beta of 2.12. The business has a 50-day moving average of $1.73.
About Ovid Therapeutics
Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome.
Read More: What does an equal weight rating mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.